Mergers & Acquisitions ·
Arcturus announces encouraging interim Phase 2 results for ARCT-810, introduces LUNAR 2.0 platform with >30-fold higher expression
ARCTArcturus Therapeutics Holdings Inc.
On September 23, 2026, Arcturus Therapeutics Holdings Inc. announced encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced its next-generation LUNAR 2.0™ mRNA delivery platform. The new platform demonstrated greater than 30-fold higher protein expression in non-human primate studies compared to previous versions, enabling the development of candidates for Phenylketonuria (PKU) and Gout. Arcturus plans to integrate ARCT-2601, which utilizes LUNAR 2.0™, into its ongoing Phase 2 study by year-end following favorable FDA feedback. Additionally, the company entered a definitive agreement to acquire myNEO, an AI discovery firm, with closing expected in October to enhance mRNA design capabilities. Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing liver and respiratory therapeutics.